6. パーキンソン病 Parkinson disease Clinical trials / Disease details


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-003456-70-IT
(EUCTR)
04/05/201802/02/2021A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson¿s Disease patientsAn Open-Label Randomized Crossover Trial, utilizing a Single-Blinded Rater to evaluate APL- 130277 compared to S.C. Apomorphine in Levodopa Responsive Subjects with Parkinson¿s Disease Complicated by Motor Fluctuations - A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson¿s Di Levodopa Responsive Patients with Parkinson¿s Disease Complicated by Motor Fluctuations (OFF episodes)
MedDRA version: 22.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
INN or Proposed INN: APOMORFINA CLORIDRATO
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Trade Name: APO-go
Product Name: s.c. apomorphine
Product Code: n/a
INN or Proposed INN: APOMORFINA CLORIDRATO
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
INN or Proposed INN: APOMORFINA CLORIDRATO
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
INN or Proposed INN: APOMORFINA CLORIDRATO
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Product Name: Apomorphine hydrochloride
Product Code: APL-130277
SUNOVION PHARMACEUTICALS INCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
106Phase 3France;Spain;Austria;Germany;United Kingdom;Italy
2EUCTR2016-000637-43-IT
(EUCTR)
05/03/201821/01/2021Safety, tolerability and efficacy study to examine APL-130277 in patients with Parkinson's Disease.An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patientswith Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes). - Safety, tolerability and efficacy study to examine APL-130277 in patients with Parkinson's Disease. Levodopa Responsive Patients with Parkinson's Disease complicated by Motor Fluctuations (OFF Episodes)
MedDRA version: 22.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Apomorphine hydrochloride
Product Code: [APL-130277]
INN or Proposed INN: APOMORFINA CLORIDRATO
Other descriptive name: Apomorphine hydrochloride
Product Name: Apomorfina cloridrato
Product Code: [APL-130277]
INN or Proposed INN: APOMORFINA CLORIDRATO
Other descriptive name: Apomorphine hydrochloride
Product Name: Apomorfina cloridrato
Product Code: [APL-130277]
INN or Proposed INN: APOMORFINA CLORIDRATO
Other descriptive name: Apomorphine hydrochloride
Product Name: Apomorfina cloridrato
Product Code: [APL-130277]
INN or Proposed INN: APOMORFINA CLORIDRATO
Other descriptive name: Apomorphine hydrochloride
SUNOVION PHARMACEUTICALS INCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
450Phase 3France;United States;Canada;Spain;Austria;Germany;United Kingdom;Italy